Document is current
Any future updates will be listed below
-
Authors
Callari, Maurizio https://orcid.org/0000-0001-5239-0918
Dugo, Matteo https://orcid.org/0000-0001-9786-2763
Barreca, Marco https://orcid.org/0000-0002-9152-236X
Győrffy, Balázs
Galbardi, Barbara
Vigano, Lucia https://orcid.org/0000-0003-4538-4354
Locatelli, Alberta https://orcid.org/0000-0003-0251-6433
Dall’Ara, Chiara https://orcid.org/0009-0004-8934-9053
Ferrarini, Marina
Bisagni, Giancarlo
Colleoni, Marco
Mansutti, Mauro
Zamagni, Claudio
Del Mastro, Lucia https://orcid.org/0000-0002-9546-5841
Zambelli, Stefania
Frassoldati, Antonio
Biasi, Olivia
Pusztai, Lajos https://orcid.org/0000-0001-9632-6686
Valagussa, Pinuccia https://orcid.org/0000-0003-3590-7916
Viale, Giuseppe
Gianni, Luca
Bianchini, Giampaolo https://orcid.org/0000-0002-6790-6267
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 12 February 2025
First Online: 4 March 2025
Competing interests
: G.V. received grants/research supports from: Roche/Genentech, Ventana Medical Systems, Dako/Agilent Technologies; honoraria or consultation feesfrom: Ventana, Dako/Agilent, Roche, MSD Oncology, AstraZeneca, Daiichi Sankyo, Pfizer, Eli Lilly. All the authors declare no conflicts of interest. L.P. has received consulting fees and honoraria for advisory board participation from Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Stemline-Menarini, GlaxoSmithKline, Genentech/Roche, Personalis, Daiichi, Natera, Exact Sciences and institutional research funding from Seagen, GlaxoSmithKline, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb. M.Co. received an institutional research grant from Roche. G.B. reports personal fees for consultancy/honorarium/advisory role: Lilly, Novartis, Pfizer, Roche, AstraZeneca, Amgen, MSD, Chugai, Sanofi, Daiichi Sankyo, EISAI, Gilead, Menarini/stemline, Exact Science, Seagen, Agendia; institutional fee for research grant from Gilead. L.G. reports grants from Roche, Breast Cancer Research Foundation (BCRF), and Pfizer during the conduct of the study; personal fees from AstraZeneca, Ely Lilly and Company, Roche, Pfizer, Seattle Genentics, Artemida Pharma, Synaffix, Menarini Ricerche, and Biomedical Insights; grants and personal fees from Zymeworks and Revolution Medicine; other support from METIS Precision Medicine, Amgen, and QU Biologics outside the submitted work; in addition, L.G. has a patent for EU N. 12195182 issued and a patent for EU N.12196177.5 issued.
